Veradermics Inc (MANE)

$37.16 -0.59 (-1.56%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 934,600
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts;...

Industry: Biotechnology
Sector: Healthcare
Phone: (228) 372-3376
Address:
470 James Street, Suite 2, New Haven, United States
Bazziggr
Bazziggr Jun. 16 at 2:10 PM
$MANE moved to ARGX
0 · Reply
Biotech_Beast
Biotech_Beast Jun. 10 at 2:01 AM
$ABSI A key readout in H2'26 for this name. Although there is competition in alopecia. $MANE https://seekingalpha.com/article/4913490-absci-corporation-a-big-binary-approaching-in-alopecia
1 · Reply
Culby
Culby Jun. 8 at 11:00 PM
$MANE where does this go from here? Have heard rumors that their female test data will be out soon???
0 · Reply
upsidetrader
upsidetrader Jun. 4 at 7:40 PM
$MANE Oh my
0 · Reply
MaverikIT
MaverikIT Jun. 4 at 2:36 PM
@Jblack500 @No_Face_character @WAJeff @cynicaloptimist @IsabellaDC @BustaCapital JB $MANE - been good
1 · Reply
Bazzzigar
Bazzzigar May. 29 at 4:15 PM
$MANE JUNK
0 · Reply
Jonita
Jonita May. 29 at 2:33 PM
$MANE in in in
0 · Reply
CaesarZane
CaesarZane May. 28 at 8:38 PM
$AZN $SUNB $MANE 📈📈📈 https://youtu.be/wFA2SX4gJYo
0 · Reply
Bazzzigar
Bazzzigar May. 15 at 6:28 PM
$MANE as expected
0 · Reply
THSSKS
THSSKS May. 1 at 5:39 AM
$MANE time to short. Typical bioturd. Results are underwhelming too, these mofos are still bald as fk.
0 · Reply
Latest News on MANE
Veradermics initiated with an Outperform at LifeSci Capital

2026-06-16T11:24:24.000Z - 4 days ago

Veradermics initiated with an Outperform at LifeSci Capital

Veradermics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 2:00 PM EDT - 11 days ago

Veradermics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Veradermics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 3:10 PM EDT - 16 days ago

Veradermics Transcript: Jefferies Global Healthcare Conference 2026

Veradermics initiated with a Buy at Needham

2026-06-02T10:00:10.000Z - 18 days ago

Veradermics initiated with a Buy at Needham

Veradermics to Present at Upcoming June Investor Conferences

May 28, 2026, 4:30 PM EDT - 22 days ago

Veradermics to Present at Upcoming June Investor Conferences

Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302' Study of VDPHL01 at the 2026 World Congress for Hair Research

May 27, 2026, 7:30 AM EDT - 24 days ago

Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302' Study of VDPHL01 at the 2026 World Congress for Hair Research

Veradermics price target raised to $135 from $120 at Citi

2026-05-18T11:25:16.000Z - 4 weeks ago

Veradermics price target raised to $135 from $120 at Citi

Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium

May 14, 2026, 7:30 AM EDT - 5 weeks ago

Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium

Veradermics Earnings release: Q1 2026

May 12, 2026, 8:30 AM EDT - 5 weeks ago

Veradermics Earnings release: Q1 2026

Veradermics Quarterly report: Q1 2026

May 12, 2026, 8:30 AM EDT - 5 weeks ago

Veradermics Quarterly report: Q1 2026

Veradermics reports Q1 net income ($27.2M) vs ($12.4M) last year

2026-05-12T11:57:22.000Z - 5 weeks ago

Veradermics reports Q1 net income ($27.2M) vs ($12.4M) last year

Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

May 12, 2026, 7:30 AM EDT - 5 weeks ago

Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics 3.84M share Secondary priced at $100.00

2026-04-30T03:35:14.000Z - 7 weeks ago

Veradermics 3.84M share Secondary priced at $100.00

Veradermics Announces Pricing of Upsized Public Offering and Private Placement

Apr 29, 2026, 10:32 PM EDT - 7 weeks ago

Veradermics Announces Pricing of Upsized Public Offering and Private Placement

Veradermics announces offering of 3.35M shares of common stock

2026-04-27T21:30:15.000Z - 7 weeks ago

Veradermics announces offering of 3.35M shares of common stock

Veradermics Announces Launch of Public Offering

Apr 27, 2026, 5:26 PM EDT - 7 weeks ago

Veradermics Announces Launch of Public Offering

Veradermics files to sell 3.35M shares of common stock

2026-04-27T21:20:43.000Z - 7 weeks ago

Veradermics files to sell 3.35M shares of common stock

Veradermics price target raised to $120 from $85 at Citi

2026-04-27T18:46:21.000Z - 7 weeks ago

Veradermics price target raised to $120 from $85 at Citi

Veradermics Transcript: Study result

Apr 27, 2026, 8:00 AM EDT - 7 weeks ago

Veradermics Transcript: Study result

Veradermics Press release: Study result

Apr 27, 2026, 8:00 AM EDT - 7 weeks ago

Veradermics Press release: Study result

Veradermics Slides: Study result

Apr 27, 2026, 8:00 AM EDT - 7 weeks ago

Veradermics Slides: Study result

Veradermics Registration statement: Registration filing

Apr 27, 2026, 8:00 AM EDT - 7 weeks ago

Veradermics Registration statement: Registration filing

Veradermics announces VDPHL01 met all primary, secondary endpoints

2026-04-27T11:20:18.000Z - 7 weeks ago

Veradermics announces VDPHL01 met all primary, secondary endpoints

Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302' Clinical Trial in Male Pattern Hair Loss

Apr 27, 2026, 7:00 AM EDT - 7 weeks ago

Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302' Clinical Trial in Male Pattern Hair Loss

Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302' Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

Apr 26, 2026, 4:00 PM EDT - 7 weeks ago

Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302' Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

Veradermics Annual report: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 2 months ago

Veradermics Annual report: Q4 2025

Veradermics Earnings release: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 2 months ago

Veradermics Earnings release: Q4 2025

Veradermics reports Q4 net loss $21.8M vs $5.7M last year

2026-03-30T11:36:51.000Z - 2 months ago

Veradermics reports Q4 net loss $21.8M vs $5.7M last year

Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates

Mar 30, 2026, 7:30 AM EDT - 2 months ago

Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates

Veradermics management to meet with Jefferies

2026-03-24T18:40:14.000Z - 3 months ago

Veradermics management to meet with Jefferies

Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting

Mar 18, 2026, 7:00 AM EDT - 3 months ago

Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting

Veradermics Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 4:20 PM EDT - 3 months ago

Veradermics Transcript: Leerink Global Healthcare Conference 2026

Veradermics to Participate in Upcoming March Investor Conferences

Mar 3, 2026, 7:00 AM EST - 3 months ago

Veradermics to Participate in Upcoming March Investor Conferences

Veradermics initiated with an Overweight at Cantor Fitzgerald

2026-03-02T13:56:49.000Z - 3 months ago

Veradermics initiated with an Overweight at Cantor Fitzgerald

Veradermics initiated with an Outperform at Leerink

2026-03-02T11:44:21.000Z - 3 months ago

Veradermics initiated with an Outperform at Leerink

Veradermics initiated with a Buy at Citi

2026-03-02T11:21:31.000Z - 3 months ago

Veradermics initiated with a Buy at Citi

Veradermics initiated with a Buy at Jefferies

2026-03-02T10:35:32.000Z - 3 months ago

Veradermics initiated with a Buy at Jefferies

Veradermics initiated with an Overweight at Cantor Fitzgerald

2026-03-01T17:25:05.000Z - 3 months ago

Veradermics initiated with an Overweight at Cantor Fitzgerald

NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell

Feb 12, 2026, 8:55 AM EST - 4 months ago

NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell

FPS

Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss

Feb 9, 2026, 7:30 AM EST - 4 months ago

Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss

Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering

Feb 5, 2026, 4:05 PM EST - 4 months ago

Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering

Veradermics Announces Pricing of Upsized Initial Public Offering

Feb 3, 2026, 9:57 PM EST - 4 months ago

Veradermics Announces Pricing of Upsized Initial Public Offering

Veradermics Slides: Corporate presentation

Feb 3, 2026, 7:00 AM EST - 4 months ago

Veradermics Slides: Corporate presentation

Veradermics Registration statement: Registration Filing

Jan 28, 2026, 7:00 AM EST - 5 months ago

Veradermics Registration statement: Registration Filing

Veradermics, Dermatology Biopharma Focused on Hair Loss, Files for NYSE IPO

Jan 9, 2026, 5:08 PM EST - 5 months ago

Veradermics, Dermatology Biopharma Focused on Hair Loss, Files for NYSE IPO

Veradermics IPO Registration Document (S-1)

Jan 9, 2026, 5:04 PM EST - 5 months ago

Veradermics IPO Registration Document (S-1)

Hair loss biotech Veradermics files for a $100 million IPO

Jan 9, 2026, 3:13 PM EST - 5 months ago

Hair loss biotech Veradermics files for a $100 million IPO

Bazziggr
Bazziggr Jun. 16 at 2:10 PM
$MANE moved to ARGX
0 · Reply
Biotech_Beast
Biotech_Beast Jun. 10 at 2:01 AM
$ABSI A key readout in H2'26 for this name. Although there is competition in alopecia. $MANE https://seekingalpha.com/article/4913490-absci-corporation-a-big-binary-approaching-in-alopecia
1 · Reply
Culby
Culby Jun. 8 at 11:00 PM
$MANE where does this go from here? Have heard rumors that their female test data will be out soon???
0 · Reply
upsidetrader
upsidetrader Jun. 4 at 7:40 PM
$MANE Oh my
0 · Reply
MaverikIT
MaverikIT Jun. 4 at 2:36 PM
@Jblack500 @No_Face_character @WAJeff @cynicaloptimist @IsabellaDC @BustaCapital JB $MANE - been good
1 · Reply
Bazzzigar
Bazzzigar May. 29 at 4:15 PM
$MANE JUNK
0 · Reply
Jonita
Jonita May. 29 at 2:33 PM
$MANE in in in
0 · Reply
CaesarZane
CaesarZane May. 28 at 8:38 PM
$AZN $SUNB $MANE 📈📈📈 https://youtu.be/wFA2SX4gJYo
0 · Reply
Bazzzigar
Bazzzigar May. 15 at 6:28 PM
$MANE as expected
0 · Reply
THSSKS
THSSKS May. 1 at 5:39 AM
$MANE time to short. Typical bioturd. Results are underwhelming too, these mofos are still bald as fk.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 30 at 8:31 PM
$MANE
0 · Reply
TheHookingBull
TheHookingBull Apr. 30 at 4:06 PM
$MANE gimme dis ballhead drug now! Need to hurry up, i’m losing my shit.
0 · Reply
CPBROGAN
CPBROGAN Apr. 30 at 1:35 PM
$MANE LOSES 21 billion and stock goes up......geez
0 · Reply
Camtanren
Camtanren Apr. 29 at 11:43 PM
$MANE I hope this company succeeds. I don’t want to go to Turkey for a transplant
0 · Reply
Bazzzigar
Bazzzigar Apr. 29 at 4:58 PM
$MANE
0 · Reply
flam70
flam70 Apr. 28 at 11:07 PM
$MANE what was the price of the offering
1 · Reply
OpenOutcrier
OpenOutcrier Apr. 28 at 12:47 PM
$MANE (-4.4% pre) Veradermics launches public offering of 3.35 million shares https://ooc.bz/l/100233
0 · Reply
ClassifiedTrades
ClassifiedTrades Apr. 28 at 11:18 AM
$HTCO $MANE $RMAX what a day yesterday
0 · Reply
topstockalerts
topstockalerts Apr. 28 at 1:52 AM
Top Gainers $HTCO $YAAS $EDSA $PAPL $MANE
0 · Reply
musky54
musky54 Apr. 27 at 11:11 PM
$MANE if you like hair growth stocks, check out ABSI
0 · Reply